Neurochem hires some of the best scientists in the world. I would not be surprised if the Alzheimer drug goes through in Europe(Europe is using more effective tactics to analyse the drug). The potential stock price could reach $60 in a matter of… More
Fools bullish on BLUS.PK
are also bullish on:
Historically, the vast majority of researchers have chosen the wrong targets to develop therapies to treat AD. And far too many potential side effects are possible with in the CNS. Neurochem's recent releases hint that the recent trial did not go… More
Fools bearish on BLUS.PK
are also bearish on: